Q3 2019 ImpediMed Ltd Earnings Call Transcript
Thank you for standing by, and welcome to the ImpediMed Quarterly Investor Conference Call. (Operator Instructions) I would now like to hand the conference over to Mr. Richard Carreon, Managing Director and CEO. Please go ahead.
Welcome, everyone, and thank you for joining us today. We're hosting this conference call to discuss our 4C for the third fiscal year quarter ending 31 March 2019. Our CFO, Morten Vigeland, is with me on the line as well. And during today's call, I'll be referencing the 4C we lodged this morning, Australia time as well as the U.S. investor slide presentation lodged on the ASX on the 18th of April, less than 2 weeks ago. I would recommend you have a copy of the slide presentation available as I move through my remarks.
Now as we normally do, we'll take questions following my comments. The financial results for the period ending 31 March were as follows. Our contracted revenue pipeline increased to $7.7 million, up 10% from the previous quarter, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |